MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

OPC-167832

CAS No. : 1883747-71-4

MCE 站：OPC-167832

产品活性：OPC-167832 是一种有效的口服活性 dprE1 抑制剂，其>IC₅₀ 为 0.258 μM。OPC-167832 具有抗结核活性，可用于由结核分枝杆菌引起的结核病的相关研究。

研究领域：Anti-infection

作用靶点：Bacterial

In Vitro: OPC-167832 exhibits very low MICs against laboratory strains of?M. tuberculosis?H37Rv (MIC: 0.0005 μg/ml) and Kurono (MIC: 0.0005 μg/ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg/ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria.
The IC₉₀ values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027?μg/ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004?μg/ml or higher.

In Vivo: OPC-167832 (oral administration; 0.625-10 mg/kg) exhibits a good pharmacokinetic??characteristic. The plasma reaches peak at 0.5 h to 1.0 h (t_max) and is eliminated with a half-life (t_1/2) of 1.3 h to 2.1 h?OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the?C_max?and AUC_t of OPC-167832 in plasma and the lungs shows dose dependency.
OPC-167832 (oral administration; 0.625-10 mg/kg; 4?weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625?mg/kg to 2.5?mg/kg. In a?M. tuberculosis?Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone.
.
OPC-167832 (oral gavage; 2.5?mg/kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate.

相关产品：Doxorubicin hydrochloride  |  Bafilomycin A1  |  Puromycin dihydrochloride  |  Staurosporine  |  Dexamethasone  |  Doxycycline (hyclate)  |  Actinomycin D  |  G-418 disulfate  |  5-Azacytidine  |  Etoposide  |  Mitomycin C  |  CCCP  |  Nigericin sodium salt  |  Resveratrol  |  Tunicamycin  |  Hygromycin B  |  Tacrolimus  |  Ionomycin  |  Vancomycin hydrochloride  |  Streptozocin  |  Tanespimycin  |  Anisomycin  |  Neomycin sulfate  |  Ampicillin sodium  |  Geldanamycin  |  Auranofin  |  Daunorubicin hydrochloride  |  Metronidazole  |  Minocycline hydrochloride  |  Gentamicin sulfate

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。